Celera Will Add to Quest's MDx Capabilities; But Reimbursement Questions Cloud Revenue Contribution
March 23, 2011
Celera Will Add to Quest's MDx Capabilities; But Reimbursement Questions Cloud Revenue Contribution
While Celera can potentially add to Quest's biomarker discovery capabilities and cardiovascular disease testing pipeline, private payors are still not reimbursing for a large share of Celera's products, which may impact how quickly Quest can see a return on its investment.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Knowledge of KIF6 Mutation Status Increases Patients' Statin Adherence, Medco Study Finds
March 28, 2012 / Pharmacogenomics Reporter - Following Merger, Express Scripts May Cut Back Medco's Personalized Medicine Programs
May 9, 2012 / Pharmacogenomics Reporter - Medco Study Suggests Genetic Testing Improves Patient Compliance with Statins
October 19, 2011 / Pharmacogenomics Reporter - FDA's Rx/Dx Draft Guidance Urges Simultaneous Development, but Addresses Alternative Scenarios
July 13, 2011 / Pharmacogenomics Reporter - Quest's Focus Dx, Scripps Developing Plavix-Response Test for 3M Integrated Cycler
March 17, 2011 / PCR Insider